Patents/Inventors

Mark K. Schlegel

Cambridge, MAUS38 patents

27 Patents

US126009652026
Modified Double Stranded Oligonucleotide
Alnylam Pharmaceuticals, Inc.
0 cites
US125841302026
Angiotensinogen (AGT) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US125656532026
ATAXIN3 (ATXN3) Rnai Agent Compositions and Methods of Use Thereof
ALNYLAM PHARMACEUTICALS, Inc.
0 cites
US125530532026
Transmembrane Serine Protease 2 (TMPRSS2) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US125459142026
Angiopoietin-like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US124801252025
Patatin-like Phospholipase Domain Containing 3 (PNPLA3) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US124735502025
Coagulation Factor V (F5) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US124160062025
Cell Death-inducing Dffa-like Effector B (CIDEB) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US124045082025
Ketohexokinase (KHK) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US123919452025
Coronavirus IRNA Compositions and Methods of Use Thereof
Vir Biotechnology, Inc.
0 cites
US123658962025
Complement Component C3 Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US123312972025
Coagulation Factor V (F5) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US122759382025
Modified RNA Agents with Reduced Off-target Effect
ALNYLAM PHARMACEUTICALS, Inc.
0 cites
US122585652025
Complement Component C3 Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US122472032025
Modified RNA Agents with Reduced Off-target Effect
Alnylam Pharmaceuticals, Inc.
0 cites
US121732892024
Hepatitis B Virus (HBV) Dsrna Agent Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US120496302024
Factor XII (F12) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US119937742024
Huntingtin (HTT) Irna Agent Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US119651662024
Complement Factor B (CFB) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US119590812024
Transthyretin (TTR) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US119268322024
Ketohexokinase (KHK) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US118667102024
Transmembrane Protease, Serine 6 (TMPRSS6) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US118346612023
Angiotensinogen (AGT) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US117252072023
Serpina1 Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US116494592023
Superoxide Dismutase 1 (SOD1) Irna Compositions and Methods of Use Thereof for Treating or Preventing Superoxide Dismutase 1-(SOD1-) Associated Neurodegenerative Diseases
Alnylam Pharmaceuticals, Inc.
0 cites
US116137512023
Angiopoietin-like 3 (ANGPTL3) Irna Compositions and Methods of Use Thereof
Alnylam Pharmaceuticals, Inc.
0 cites
US115979322023
Chirally-enriched Double-stranded RNA Agents
Alnylam Pharmaceuticals, Inc.
0 cites